𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen

✍ Scribed by Guang-Hong Tan; Yu-Quan Wei; Ling Tian; Xia Zhao; Li Yang; Jiong Li; Qiu-Ming He; Yang Wu; Yan-Jun Wen; Tao Yi; Zhen-Yu Ding; Bin Kan; Yong-Qiu Mao; Hong-Xin Deng; Hong-Li Li; Chun-Hua Zhou; Chun-Hua Fu; Fei Xiao; Xiao-Wei Zhang

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
359 KB
Volume
34
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Angiogenesis play a critical role in tumor growth and metastasis. Increasing evidence suggests that endoglin is a powerful marker of angiogenesis in solid malignancies. Thus, breaking of immune tolerance of self‐endoglin‐associated angiogenesis is an attractive approach to cancer therapy. To test this concept, we recombined the extracellular domains of porcine endoglin, and used it as a xenogeneic vaccine. We found that immunotherapy with porcine endoglin was effective at both protective and therapeutic anti‐tumor immunity in several mouse tumor models. Autoantibodies against mouseendoglin were identified by Western blot and ELISA. IgG1 and IgG2b were substantially increased. Anti‐endoglin antibody‐producing B cells were detectable by ELISPOT assay. There was endothelial deposition of immunoglobulins within tumors. The anti‐tumor activity was also induced by the adoptive transfer of the purified immunoglobulins. Angiogenesis was apparently inhibited within the tumor tissues and on the alginate beads. The increased apoptotic cells were found within the tumor tissues from the mice treated with porcine endoglin. The anti‐tumor activity and production of autoantibodies againstmouse endoglin could be abrogated by depletion of CD4^+^ T lymphocytes. Remarkably, no marked toxicity was found in the immunized mice. These observations may provide an alternative rationalstrategy for active cancer immunotherapy.

📜 SIMILAR VOLUMES

Combination of low-dose cisplatin and re
Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities
✍ Guang-hong Tan; Ling Tian; Yu-quan Wei; Xia Zhao; Jiong Li; Yang Wu; Yan-jun Wen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 204 KB

## Abstract Angiogenesis is critical to the growth and metastasis of solid tumors, and acquired drug resistance is one of the major hindrances to chemotherapy. Thus, we sought a rational strategy using the combination of antiangiogenic biotherapy and chemotherapy for cancer therapy. We explored the

Immunotherapy with recombinant SFV-repli
Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression
✍ Paula Colmenero; Margaret Chen; Esmeralda Castaños-Velez; Peter Liljeström; Mika 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 479 KB

## Abstract Replicons based on alphaviruses are emerging as candidate vectors for vaccination and gene therapy purposes. We have reported previously that mice vaccinated with a recombinant Semliki Forest virus (a member of the alphavirus genus) carrying the gene encoding the P815A tumor antigen (rS

Specific active immunotherapy in patient
Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial
✍ Ariel Hollinshead; E. George Elias; Myron Arlen; Barbara Buda; Maria Mosley; Jos 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 838 KB

Twenty-two patients received specific active immunotherapy (TAA vaccine once per month for 3 months), with the duration of follow-up, as of July 1984, ranging from 3 months to 36 months (median, 21 months). Of these, seven had Dukes Bz, seven had Dukes C, and eight had Dukes D lesions. All received